The Cancer Researcher
  • Home
  • About
  • The Cancer Researcher Podcast
  • #KeepResearchCurious
No Result
View All Result
  • Home
  • About
  • The Cancer Researcher Podcast
  • #KeepResearchCurious
No Result
View All Result
The Cancer Researcher
No Result
View All Result

News Summary: CancerSEEK blood test, immune system vs. CRISPR

July 17, 2018
News Summary: CancerSEEK blood test, immune system vs. CRISPR

Credit: Illustration by Elizabeth Cook & Kaitlin Lindsay

CancerSEEK blood test detects 8 common cancers

A team of researchers from Johns Hopkins University have trialled a blood test, CancerSEEK, that could identify non-metastastic cancers in the ovary, liver, esophagus, pancreas, stomach, colorectal, lung, and breast.

The CancerSEEK test looks for mutations in 16 genes that regularly arise in cancer and eight proteins that are often released. It could allow for earlier detection of cancers as well as being non-invasive and low-cost.

The test was trialled on over 1000 patients already diagnosed with non-metastatic cancers, and detected cancer with a sensitivity of 69 to 98% (depending on cancer type). The results have been published in the journal Science. View the abstract here.

EACR Past President Professor Richard Marais was interviewed by the BBC about the significance of the development. Watch a short clip here.


The immune system could thwart some CRISPR gene therapies

The body’s own immune system could thwart some efforts to develop gene therapies based on the trendy genome-editing tool called CRISPR-Cas9, according to a study released on 5 January.

The study is a Preprint at bioRxiv: Identification of Pre-Existing Adaptive Immunity to Cas9 Proteins in Humans

Click here to read an in-depth Nature News article explaining the process


Thermo Fisher Scientific and Illumina sign agreement to provide research market broader access to Ion AmpliSeq technology

Thermo Fisher Scientific and Illumina, Inc. have signed a commercial agreement that enables Illumina to sell Thermo Fisher’s  Ion AmpliSeq technology to researchers who conduct scientific studies on Illumina’s next-generation sequencing platforms. Ion AmpliSeq technology is used to capture DNA and RNA from minute amounts of samples for application in multiple areas of research.

The agreement enables Illumina customers to utilize targeted resequencing as a follow-up to larger-scale exome and whole genome discovery studies.

Read the full announcement on Business Wire


 

Tags: CancerSEEKCRISPRnews summary

Related Posts

Daniel Kirschenbaum receives the 2026 EACR-Mark Foundation-Pezcoller Foundation Rising Star Award

Daniel Kirschenbaum receives the 2026 EACR-Mark Foundation-Pezcoller Foundation Rising Star Award

January 16, 2026

We are pleased to announce that Daniel Kirschenbaum has been selected as the recipient of the 2026 EACR-Mark Foundation-Pezcoller Foundation Rising Star Award. Established in 2023,...

“This work will allow me to expand my work on cancer genomics to a functional level”: Isidro Cortés-Ciriano on his Rising Star Award

Isidro Cortés-Ciriano two years into winning the Rising Star Award 2023

December 19, 2025

Isidro Cortés-Ciriano was the 2023 recipient of the EACR-Mark Foundation-Pezcoller Foundation Rising Star Award, which granted him funding to commence the project he proposed as part...

Scientific Highlights from Cancer Neuroscience

Scientific Highlights from Cancer Neuroscience

December 19, 2025

Dr. Alexandra Boitor, EACR Scientific Manager, gives a few of the highlights from Cancer Neuroscience (Bilbao, 14-16 October 2025). Recent interdisciplinary research shows that the nervous...

The Cancer Researcher EACR logo

About Us

The Cancer Researcher is an online magazine for the cancer research community from the European Association for Cancer Research.

The EACR, a registered charity, is a global community for those working and studying in cancer research. Our mission is “The advancement of cancer research for the public benefit: from basic research to prevention, treatment and care.”

RECENT POSTS

EACR Travel Grant winners at Cancer Neuroscience 2025
Community

EACR Travel Grant winners at Cancer Neuroscience 2025

January 30, 2026
“It is a journey rather than a race toward a single endpoint”: Interview with Ayelet Erez, winner of the 2026 Pezcoller-Marina Larcher Fogazzaro-EACR Women in Cancer Research Award
Community

“It is a journey rather than a race toward a single endpoint”: Interview with Ayelet Erez, winner of the 2026 Pezcoller-Marina Larcher Fogazzaro-EACR Women in Cancer Research Award

January 19, 2026
The Cancer Researcher

© 2025 EACR

Navigate site

  • About
  • Privacy
  • Main EACR website

Follow us

No Result
View All Result
  • Home
  • About
  • The Cancer Researcher Podcast
  • #KeepResearchCurious

© 2025 EACR